Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis

This study has been completed.
Sponsor:
Information provided by:
Alizyme
ClinicalTrials.gov Identifier:
NCT00299013
First received: March 2, 2006
Last updated: April 24, 2008
Last verified: April 2008
  Purpose

The purpose of this study is to investigate whether a novel dosage form of a prednisolone ester, called COLAL-PRED®, is useful in the treatment of ulcerative colitis.


Condition Intervention Phase
Ulcerative Colitis
Drug: COLAL-PRED®
Drug: Prednisolone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised, Double Blind, Double Dummy, Active Comparator Controlled, Parallel Group Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Alizyme:

Primary Outcome Measures:
  • Disease activity index [ Time Frame: After 4 and 8 weeks of treatment ] [ Designated as safety issue: No ]
  • Cortisol levels [ Time Frame: After 4 and 8 weeks of treatment ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Simple clinical colitis activity index [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Endoscopy [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Laboratory tests [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 796
Study Start Date: March 2006
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
Drug: Prednisolone
Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
Experimental: 2
COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
Drug: COLAL-PRED®
COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Other Name: Prednisolone sodium metasulfobenzoate.
Experimental: 3
COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
Drug: COLAL-PRED®
COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Other Name: Prednisolone sodium metasulfobenzoate.
Experimental: 4
COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
Drug: COLAL-PRED®
COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Other Name: Prednisolone sodium metasulfobenzoate.

Detailed Description:

Ulcerative colitis is a disease that causes inflammation of the large bowel, causing fever, diarrhoea, dehydration and other symptoms. Standard treatment for ulcerative colitis includes general medical treatments such as fluid and salt replacement and attention to diet. Anti-inflammatory medicines such as steroids (e.g. prednisolone) and aminosalicylates (e.g. mesalazine) are the main drug treatments.

This study will investigate whether COLAL-PRED®, a novel dosage form of a prednisolone ester, is safe and effective in the treatment of ulcerative colitis, compared with the standard treatment (conventional prednisolone) and also to determine which dose which will work best for future patients.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Endoscopically confirmed diagnosis of ulcerative colitis
  • Score of 6-10 on the Disease Activity Index (DAI)
  • Moderate to severe mucosal appearance

Exclusion Criteria:

  • Previous colonic surgery
  • Other treatments for ulcerative colitis that have not been stabilised
  • Clinically significant diabetes, heart failure, unstable angina, cirrhosis, renal failure
  • History of tuberculosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00299013

  Show 86 Study Locations
Sponsors and Collaborators
Alizyme
Investigators
Principal Investigator: Christopher Hawkey University Hospital, Nottingham
  More Information

No publications provided

Responsible Party: Research and Development Director, Alizyme
ClinicalTrials.gov Identifier: NCT00299013     History of Changes
Other Study ID Numbers: ATL2502/020/CL
Study First Received: March 2, 2006
Last Updated: April 24, 2008
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Alizyme:
Ulcerative colitis

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Colonic Diseases
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Pathologic Processes
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 29, 2014